207 related articles for article (PubMed ID: 37940982)
21. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
22. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
23. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T
BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851
[TBL] [Abstract][Full Text] [Related]
24. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
25. Umbilical Cord Blood-Derived M1 Macrophage Exosomes Loaded with Cisplatin Target Ovarian Cancer
Zhang X; Wang J; Liu N; Wu W; Li H; Lu W; Guo X
Mol Pharm; 2023 Nov; 20(11):5440-5453. PubMed ID: 37819754
[TBL] [Abstract][Full Text] [Related]
26. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
Meng W; Tai Y; Zhao H; Fu B; Zhang T; Liu W; Li H; Yang Y; Zhang Q; Feng Y; Chen G
Med Sci Monit; 2017 Mar; 23():1295-1304. PubMed ID: 28291769
[TBL] [Abstract][Full Text] [Related]
28. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
29. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
30. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
31. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract][Full Text] [Related]
32. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
33. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
34. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2.
Liu R; Guo H; Lu S
Cancer Med; 2018 Sep; 7(9):4598-4609. PubMed ID: 30019389
[TBL] [Abstract][Full Text] [Related]
35. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
36. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
Brum MCM; Dos Santos Guimaraes I; Ferreira LB; Rangel LBA; Maia RC; Nestal De Moraes G; Gimba ERP
Oncol Rep; 2021 Feb; 45(2):652-664. PubMed ID: 33416171
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
40. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]